Immunopathogenesis of vitiligo

Autoimmunity Reviews

Volumn 10, Issue 12, 2011, Pages 762-765

  Sandoval Cruz, Manuel ^a   García Carrasco, Mario ^a,b   Sánchez Porras, Renán ^a   Mendoza Pinto, Claudia ^a   Jiménez Hernández, Mario ^a   Munguía Realpozo, Pamela ^a   Ruiz Argüelles, Alejandro ^c  

^a INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^b BENEMÉRITA UNIVERSIDAD AUTÓNOMA DE PUEBLA   (Mexico)

^c Laboratorios Clinicos de Puebla   (Mexico)

Author keywords

Autoimmunity; Melanocyte; Pathogenesis; Vitiligo

Indexed keywords

AUTOANTIBODY; AUTOANTIGEN; CYTOKINE; ENDOTHELIN 1; FIBROBLAST GROWTH FACTOR 2; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN G ANTIBODY; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 17; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 6; INTERLEUKIN 8; STEM CELL FACTOR; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; AUTOIMMUNE DISEASE; AUTOIMMUNITY; B LYMPHOCYTE; CD4 CD8 RATIO; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DAMAGE; CELLULAR IMMUNITY; COMPLEMENT DEPENDENT CYTOTOXICITY; CYTOKINE PRODUCTION; HUMAN; HUMORAL IMMUNITY; IMMUNOPATHOGENESIS; MELANOCYTE; MONONUCLEAR CELL; NONHUMAN; REVIEW; SKIN BIOPSY; T LYMPHOCYTE; VITILIGO;

AUTOIMMUNE DISEASES; AUTOIMMUNITY; HUMANS; MELANOCYTES; VITILIGO;

EID: 79960180411     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2011.02.004     Document Type: Review

References (42)

1. Guerra L., Dellambra E., Brescia S., Raskovic D. Vitiligo: pathogenetic hypotheses and targets for current therapies. Curr Drug Metab Jun 1 2010, 11(5):451-467.
2. Kakourou T. Vitiligo in children. World J Pediatr Nov 2009, 5(4):265-268.
3. Matz H., Vitiligo Tur E. Curr Probl Dermatol 2007, 35:78-102.
4. Korsunskaya I.M., Suvorova K.N., Dvoryankova E.V. Modern aspects of vitiligo pathogenesis. Dokl Biol Sci Jan-Feb 2003, 388:38-40.
5. Halder R.M., Chappell J.L. Vitiligo update. Semin Cutan Med Surg Jun 2009, 28(2):86-92.
6. Ongenae K., Van Geel N., Naeyaert J.M. Evidence for an autoimmune pathogenesis of vitiligo. Pigment Cell Res Apr 2003, 16(2):90-100.
7. Passeron T., Ortonne J.P. Physiopathology and genetics of vitiligo. J Autoimmun 2005, 25(Suppl):63-68.
8. Michelsen D. The double strike hypothesis of the vitiligo pathomechanism: new approaches to vitiligo and melanoma. Med Hypotheses Jan 2010, 74(1):67-70.
9. Abu Tahir M., Pramod K., Ansari S.H., Ali J. Current remedies for vitiligo. Autoimmun Rev 2010, 9(7):516-520. May.
10. Kemp E.H., Gavalas N.G., Gawkrodger D.J., Weetman A.P. Autoantibody responses to melanocytes in the depigmenting skin disease vitiligo. Autoimmun Rev Jan 2007, 6(3):138-142.
11. Ali R., Ahsan M.S., Azad M.A., Ullah M.A., Bari W., Islam S.N., Yeasmin S., Hasnat A. Immunoglobulin levels of vitiligo patients. Pak J Pharm Sci Jan 2010, 23(1):97-102.
12. Li Y.L., Yu C.L., Yu H.S. IgG anti-melanocyte antibodies purified from patients with active vitiligo induce HLA-DR and intercellular adhesion molecule-1 expression and an increase in interleukin-8 release by melanocytes. J Invest Dermatol Dec 2000, 115(6):969-973.
13. Ruiz-Argüelles A., Brito G.J., Reyes-Izquierdo P., Pérez-Romano B., Sánchez-Sosa S. Apoptosis of melanocytes in vitiligo results from antibody penetration. J Autoimmun Dec 2007, 29(4):281-286.
14. Waterman E.A., Gawkrodger D.J., Watson P.F., Weetman A.P., Kemp E.H. Autoantigens in vitiligo identified by the serological selection of a phage-displayed melanocyte cDNA expression library. J Invest Dermatol Jan 2010, 130(1):230-240.
15. Le Poole I.C., Wañkowicz-Kaliñska A., van den Wijngaard R.M., Nickoloff B.J., Das P.K. Autoimmune aspects of depigmentation in vitiligo. J Investig Dermatol Symp Proc Jan 2004, 9(1):68-72.
16. Wańkowicz-Kalińska A., van den Wijngaard R.M., Tigges B.J., Westerhof W., Ogg G.S., Cerundolo V., Storkus W.J., Das P.K. Immunopolarization of CD4+ and CD8+ T cells to Type-1-like is associated with melanocyte loss in human vitiligo. Lab Invest May 2003, 83(5):683-695.
17. Ogg G.S., Rod Dunbar P., Romero P., Chen J.L., Cerundolo V. High frequency of skin-homing melanocyte-specific cytotoxic T lymphocytes in autoimmune vitiligo. J Exp Med Sep 21 1998, 188(6):1203-1208.
18. Palermo B., Campanelli R., Garbelli S., Mantovani S., Lantelme E., Brazzelli V., Ardigó M., Borroni G., Martinetti M., Badulli C., Necker A., Giachino C. Specific cytotoxic T lymphocyte responses against Melan-A/MART1, tyrosinase and gp100 in vitiligo by the use of major histocompatibility complex/peptide tetramers: the role of cellular immunity in the etiopathogenesis of vitiligo. J Invest Dermatol Aug 2001, 117(2):326-332.
19. van den Boorn J.G., Konijnenberg D., Dellemijn T.A., van der Veen J.P., Bos J.D., Melief C.J., Vyth-Dreese F.A., Luiten R.M. Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients. J Invest Dermatol Sep 2009, 129(9):2220-2232.
20. Steitz J., Wenzel J., Gaffal E., Tüting T. Initiation and regulation of CD8+T cells recognizing melanocytic antigens in the epidermis: implications for the pathophysiology of vitiligo. Eur J Cell Biol Dec 2004, 83(11-12):797-803.
21. van den Wijngaard R., Wankowicz-Kalinska A., Le Poole C., Tigges B., Westerhof W., Das P. Local immune response in skin of generalized vitiligo patients. Destruction of melanocytes is associated with the prominent presence of CLA+T cells at the perilesional site. Lab Invest Aug 2000, 80(8):1299-1309.
22. Oyarbide-Valencia K., van den Boorn J.G., Denman C.J., Li M., Carlson J.M., Hernandez C., Nishimura M.I., Das P.K., Luiten R.M., Le Poole I.C. Therapeutic implications of autoimmune vitiligo T cells. Autoimmun Rev Aug 2006, 5(7):486-492.
23. al Badri A.M., Foulis A.K., Todd P.M., Gariouch J.J., Gudgeon J.E., Stewart D.G., Gracie J.A., Goudie R.B. Abnormal expression of MHC class II and ICAM-1 by melanocytes in vitiligo. J Pathol Feb 1993, 169(2):203-206.
24. Steitz J., Brück J., Lenz J., Büchs S., Tüting T. Peripheral CD8+ T cell tolerance against melanocytic self-antigens in the skin is regulated in two steps by CD4+ T cells and local inflammation: implications for the pathophysiology of vitiligo. J Invest Dermatol Jan 2005, 124(1):144-150.
25. Gattinoni L., Ranganathan A., Surman D.R., Palmer D.C., Antony P.A., Theoret M.R., Heimann D.M., Rosenberg S.A., Restifo N.P. CTLA-4 dysregulation of self/tumor-reactive CD8+ T-cell function is CD4+ T-cell dependent. Blood Dec 1 2006, 108(12):3818-3823.
26. Yamauchi P.S., Nguyen N.Q., Grimes P.E. Idiopathic CD4+T-cell lymphocytopenia associated with vitiligo. J Am Acad Dermatol May 2002, 46(5):779-782.
27. Le Poole I.C., Stennett L.S., Bonish B.K., Dee L., Robinson J.K., Hernandez C., Hann S.K., Nickoloff B.J. Expansion of vitiligo lesions is associated with reduced epidermal CDw60 expression and increased expression of HLA-DR in perilesional skin. Br J Dermatol Oct 2003, 149(4):739-748.
28. Zamani M., Tabatabaiefar M.A., Mosayyebi S., Mashaghi A., Mansouri P. Possible association of the CD4 gene polymorphism with vitiligo in an Iranian population. Clin Exp Dermatol Jul 2010, 35(5):521-524.
29. Klarquist J., Denman C.J., Hernandez C., Wainwright D.J., Strickland F.M., Overbeck A., Mehrotra S., Nishimura M.I., Le Poole I.C. Reduced skin homing by functional Treg in vitiligo. Pigment Cell Melanoma Res Apr 2010, 23(2):276-286.
30. Pichler R., Sfetsos K., Badics B., Gutenbrunner S., Berg J., Auböck J. Lymphocyte imbalance in vitiligo patients indicated by elevated CD4+/CD8+ T-cell ratio. Wien Med Wochenschr 2009, 159(13-14):337-341.
31. Basak P.Y., Adiloglu A.K., Koc I.G., Tas T., Akkaya V.B. Evaluation of activatory and inhibitory natural killer cell receptors in non-segmental vitiligo: a flow cytometric study. J Eur Acad Dermatol Venereol Aug 2008, 22(8):970-976.
32. Grimes P.E., Ghoneum M., Stockton T., Payne C., Kelly A.P., Alfred L. T cell profiles in vitiligo. J Am Acad Dermatol Feb 1986, 14(2 Pt 1):196-201.
33. Mahmoud F., Abul H., Haines D., Al-Saleh C., Khajeji M., Whaley K. Decreased total numbers of peripheral blood lymphocytes with elevated percentages of CD4+CD45RO+and CD4+CD25+ of T-helper cells in non-segmental vitiligo. J Dermatol Feb 2002, 29(2):68-73.
34. Le Poole I.C., van den Wijngaard R.M., Westerhof W., Das P.K. Presence of T cells and macrophages in inflammatory vitiligo skin parallels melanocyte disappearance. Am J Pathol Apr 1996, 148(4):1219-1228.
35. Gavalas N.G., Gottumukkala R.V., Gawkrodger D.J., Watson P.F., Weetman A.P., Kemp E.H. Mapping of melanin-concentrating hormone receptor 1 B cell epitopes predicts two major binding sites for vitiligo patient autoantibodies. Exp Dermatol May 2009, 18(5):454-463.
36. Yeo U.C., Yang Y.S., Park K.B., Sung H.T., Jung S.Y., Lee E.S., Shin M.H. Serum concentration of the soluble interleukin-2 receptor in vitiligo patients. J Dermatol Sci Apr 1999, 19(3):182-188.
37. Yu H.S., Chang K.L., Yu C.L., Li H.F., Wu M.T., Wu C.S., Wu C.S. Alterations in IL-6, IL-8, GM-CSF, TNF-alpha, and IFN-gamma release by peripheral mononuclear cells in patients with active vitiligo. J Invest Dermatol Apr 1997, 108(4):527-529.
38. Basak P.Y., Adiloglu A.K., Ceyhan A.M., Tas T., Akkaya V.B. The role of helper and regulatory T cells in the pathogenesis of vitiligo. J Am Acad Dermatol Feb 2009, 60(2):256-260.
39. Moretti S., Spallanzani A., Amato L., Hautmann G., Gallerani I., Fabiani M., Fabbri P. New insights into the pathogenesis of vitiligo: imbalance of epidermal cytokines at sites of lesions. Pigment Cell Res Apr 2002, 15(2):87-92.
40. Moretti S., Fabbri P., Baroni G., Berti S., Bani D., Berti E., Nassini R., Lotti T., Massi D. Keratinocyte dysfunction in vitiligo epidermis: cytokine microenvironment and correlation to keratinocyte apoptosis. Histol Histopathol Jul 2009, 24(7):849-857.
41. Namian A.M., Shahbaz S., Salmanpoor R., Namazi M.R., Dehghani F., Kamali-Sarvestani E. Association of interferon-gamma and tumor necrosis factor alpha polymorphisms with susceptibility to vitiligo in Iranian patients. Arch Dermatol Res Jan 2009, 301(1):21-25.
42. Zhao M., Gao F., Wu X., Tang J., Lu Q. Abnormal DNA methylation in peripheral blood mononuclear cells from patients with vitiligo. Br J Dermatol Oct 2010, 163(4):736-742.